About dasatinib
Tyrosine kinase inhibitor
Used for
- Treats chronic myeloid leukemia (CML).
- Treats Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Usual adult dose
Usually 100 mg once daily for chronic-phase CML; 140 mg once daily for advanced CML or Ph+ ALL.
Usual dose in children
For children with Ph+ CML or Ph+ ALL, dose is based on body weight or body surface area, once daily.
Common side effects
- Low blood cell counts
- Fluid buildup, including around the lungs
- Diarrhea, nausea, or headache
- Bleeding or abnormal heart rhythm
Important warnings
- Can cause severe low blood counts, bleeding, or fluid buildup.
- Seek urgent care for breathing difficulty, chest pain, fainting, or unusual bleeding.
- May prolong the heart’s electrical rhythm; correct low potassium or magnesium.
- Avoid grapefruit and grapefruit juice; do not stop treatment without the prescriber.
Pregnancy
May harm an unborn baby. Pregnancy should be avoided during treatment and for 30 days after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for two weeks after the last dose.
Interactions
- Strong CYP3A4 inhibitors can raise dasatinib levels; strong inducers can lower them.
- Acid-reducing medicines, especially proton pump inhibitors, can reduce absorption.
- Blood thinners and medicines that impair platelet function can increase bleeding.
- Grapefruit can increase drug levels; avoid it.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.